Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KN046 and Regorafenib in Metastatic Microsatellite-Stable Colorectal Cancer
NCT05985109Phase 2Terminated
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Oct 2023
- Primary completion
- Sep 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of erfonrilimab in colorectal cancer (CRC), sponsored by Peking University Cancer Hospital & Institute. Started Oct 2023; status: terminated.
02
Drugs
erfonrilimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05985109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05985109.